33 / 46
Page 74
Notes:
conferenceseries
.com
Volume 7, Issue 5 (Suppl)
J Clin Trials, an open access journal
ISSN:2167-0870
Clinical Trials 2017
September 11-13, 2017
September 11-13, 2017 San Antonio, USA
4
th
International Conference on
Cl inical Tr ial s
Old chemicals, now as potential life savers against ischemic and reperfusion injuries
Myoung-Gwi Ryou
Tarleton State University, USA
I
schemia and reperfusion (I/R) injuries are critical life-threatening diseases and may end up with serious adult disability, but
FDA-approved treatment is limited. Classical chemicals such as methylene blue (MB) and pyruvate have been revisited to
evaluate protective roles in I/R injuries including ischemic stroke and myocardial infarction. Oxidative stress and inefficient
energy metabolism are the pivotal contributors to I/R diseases. Results from bench studies support that both pyruvate and MB
increases ATP production and have potent antioxidant effect. However, detailed mechanisms of beneficial effects are different
between pyruvate and MB. MB rather prevents electron leakage through electron transport chain in the mitochondria and by
which energy metabolism enhanced. On the other hand, pyruvate enhanced endogenous redox state, such as the ratio of GSH
to GSSG, and improves ATP production by providing metabolic resources required for the glucose metabolism. Furthermore,
the effects of MB and pyruvate on the gene regulation have been investigated. Both MB and pyruvate enhances cellular ability
to resist against ischemic stress by activating hypoxia inducible factor-1. In conclusion, pyruvate and MB, old chemicals, have
two-phase effects on I/R injury. Short-term effect, MB and pyruvate can protect the victims of various I/R diseases by reducing
oxidative stress and enhancing energy metabolisms. The long-term effects of MB and pyruvate allow the conversion of gene
profiles to help protect and restore from I/R damage.
Biography
Myoung-Gwi Ryou has completed his PhD in 2008 from University of North Texas Health Science Center and Post-doctoral studies from University of Texas
Southwestern Medical School. He is the Director and an Assistant Professor, Dept. of Medical Laboratory Science and Adjunct Faculty in the UNTHSC. He has
published more than 23 papers and chapters in reputed journals and has been serving as an Editorial Board Member of several peer reviewed journals.
ryou@tarleton.eduMyoung-Gwi Ryou, J Clin Trials 2017, 7:5 (Suppl)
DOI: 10.4172/2167-0870-C1-019